XOMA Royalty (XOMA) Amortization of Deferred Charges (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Amortization of Deferred Charges came in at $332000.0 in Q1 2026, down 22.25% year-on-year from $427000.0 in Q1 2025, and up 33.33% quarter-over-quarter from $249000.0 in Q4 2025.
XOMA Royalty (XOMA) Amortization of Deferred Charges (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Amortization of Deferred Charges across 14 years of filings, most recently posting $332000.0 for Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $332000.0, down 22.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 12.3% YoY), and the FY2025 annual result was $1.4 million, up 2.59% from the prior year.
- Amortization of Deferred Charges came in at $332000.0 for Q1 2026 at XOMA Royalty, up from $249000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $427000.0 in Q1 2025 to a low of $249000.0 in Q4 2025.
- The 3-year median for Amortization of Deferred Charges is $332000.0 (2026), against an average of $340777.8.
- Peak annual rise in Amortization of Deferred Charges reached 39.54% in 2025, while the deepest fall reached 29.66% in 2025.
- XOMA Royalty's Amortization of Deferred Charges stood at $354000.0 in 2024, then dropped by 29.66% to $249000.0 in 2025, then surged by 33.33% to $332000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $332000.0 (Q1 2026), $249000.0 (Q4 2025), and $387000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 332,000.00 |
| Mar 31, 2026 | 332,000.00 |
| Dec 31, 2025 | 249,000.00 |
| Dec 31, 2025 | 249,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Jun 30, 2025 | 322,000.00 |
| Jun 30, 2025 | 322,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Sep 30, 2024 | 408,000.00 |
| Sep 30, 2024 | 408,000.00 |
| Jun 30, 2024 | 282,000.00 |
| Jun 30, 2024 | 282,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Jun 30, 2021 | 73,000.00 |
| Jun 30, 2021 | 73,000.00 |